Carisma Therapeutics Inc. financial data

Symbol
CARM on Nasdaq
Industry
Pharmaceutical Preparations
Location
3675 Market Street, Suite 401, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Sesen Bio, Inc. (to 3/6/2023), Eleven Biotherapeutics, Inc. (to 5/16/2018)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 306 % -52.9%
Debt-to-equity 115 % +62.9%
Return On Equity 871 %
Return On Assets -118 % -64.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.8M shares +0.59%
Common Stock, Shares, Outstanding 41.8M shares +2.81%
Entity Public Float 53.1M USD -80.7%
Common Stock, Value, Issued 41K USD +2.5%
Weighted Average Number of Shares Outstanding, Basic 41.5M shares +23.7%
Weighted Average Number of Shares Outstanding, Diluted 41.5M shares +23.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19.6M USD +31.5%
Research and Development Expense 59.7M USD -19.5%
General and Administrative Expense 22.1M USD -25%
Operating Income (Loss) -62.2M USD +29.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -60.5M USD +30.4%
Earnings Per Share, Basic -1.46 USD/shares +43.6%
Earnings Per Share, Diluted -1.46 USD/shares +43.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.9M USD -76.9%
Marketable Securities, Current 0 USD -100%
Cash, Cash Equivalents, and Short-term Investments 17.9M USD -76.9%
Assets, Current 23.8M USD -70.4%
Property, Plant and Equipment, Net 7.38M USD
Operating Lease, Right-of-Use Asset 2.04M USD -6.12%
Assets 30.5M USD -66%
Accounts Payable, Current 2.08M USD -47.1%
Employee-related Liabilities, Current 4.88M USD +57.4%
Accrued Liabilities, Current 7.45M USD -2.79%
Liabilities, Current 16.1M USD +0.92%
Operating Lease, Liability, Noncurrent 724K USD -15.8%
Other Liabilities, Noncurrent 318K USD -65.7%
Liabilities 58.4M USD -7.39%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -306M USD -24.7%
Stockholders' Equity Attributable to Parent 26.5M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -27.9M USD -205%
Liabilities and Equity 30.5M USD -66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 1.35M USD -98%
Net Cash Provided by (Used in) Investing Activities -17K USD +99.5%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 41.8M shares +2.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.9M USD -76.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 50K USD +11.1%
Deferred Tax Assets, Valuation Allowance 154M USD +15.2%
Deferred Tax Assets, Gross 155M USD +15.1%
Operating Lease, Liability 1.56M USD -30.9%
Payments to Acquire Property, Plant, and Equipment 17K USD -87.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.5M USD +30.4%
Lessee, Operating Lease, Liability, to be Paid 1.81M USD -30.7%
Operating Lease, Liability, Current 832K USD -40.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 225K USD +2.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 927K USD -38.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 253K USD -29.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 233K USD +3.1%
Deferred Tax Assets, Operating Loss Carryforwards 87.7M USD +20.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 240K USD +3%
Operating Lease, Payments 1.46M USD +1.04%
Additional Paid in Capital 278M USD +2.22%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.28M USD +9.24%
Share-based Payment Arrangement, Expense 3.65M USD +57.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%